Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prime REMIX: LD-TBI and CAR T-cell Therapy in Relapsed/Refractory DLBCL and Multiple Myeloma
NCT07725406Phase 1Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lisocabtagene maraleucel, axicabtagene ciloleucel and ciltacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM) (10 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Incidence of Dose-Limiting Toxicities at Day 28. Started Nov 2026; status: recruiting.
02
Drugs
lisocabtagene maraleucelaxicabtagene ciloleucelciltacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07725406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725406.